Latest Headlines

  1. Lupin Announces The Approval And Launch Of Brivaracetam Oral Solution In The United States 2/24/2026

    Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution 10 mg/mL.

  2. Draper And Partners Awarded ARPA-H Funding To Develop New In Silico Models Of Human Physiology For Drug Development 2/24/2026

    Draper recently received an up to $26.7 million other transaction award (OTA) from the Advanced Research Projects Agency for Health (ARPA-H). The award supports the agency's Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) program, which will develop a new generation of in silico models of human physiology based on data from New Approach Methodologies (NAMs) to inform the drug development process.

  3. Angelini Pharma And Quiver Bioscience Announce Strategic Research Collaboration And Licensing Agreement To Discover And Advance Novel Therapeutics For Genetic Epilepsies 2/23/2026

    Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies.

  4. FDA Accepts New Drug Application For Genentech's Giredestrant In ESR1-Mutated, ER-Positive Advanced Breast Cancer 2/20/2026

    Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application for giredestrant, an investigational oral therapy, in combination with everolimus for the treatment of adult patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer following recurrence or progression on a prior endocrine-based regimen.

  5. Sygnature Discovery Unveils Strategic Rebrand To Cement Status As A Global Drug Discovery Partner 2/19/2026

    Sygnature Discovery, a leading drug discovery contract research organisation (CRO), has today announced a strategic brand relaunch, including a new website, cementing its position as a global drug discovery partner.

  6. Sibel Health Receives FDA Acceptance Into Drug Development Tool Qualification Program For Innovative Cough Monitoring Sensor 2/19/2026

    Sibel Health, a leader in medical-grade wearable sensor technology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's recent Letter of Intent (LOI) into the Clinical Outcome Assessment (COA) Qualification Program under the Drug Development Tool (DDT) framework. 

  7. Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation For AFTX-201 In BAG3-Associated Dilated Cardiomyopathy (DCM) 2/18/2026

    Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that the European Medicines Agency (EMA) has granted Orphan Drug designation to Affinia for AFTX-201.

  8. Merck And Mayo Clinic Announce New Research And Development Collaboration To Support AI-Enabled Drug Discovery And Precision Medicine 2/18/2026

    Merck, known as MSD outside of the U.S. and Canada, and Mayo Clinic, the world's top-ranked hospital system, today announced a research and development agreement to apply artificial intelligence (AI), advanced analytics and multimodal clinical data to support drug discovery and development.

  9. Insilico Medicine Initiates AI-Driven Collaboration With Leading Global Cancer Center To Identify Novel Targets For Gastroesophageal Cancers 2/17/2026

    Insilico Medicine (“Insilico”, 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and Memorial Sloan Kettering Cancer Center (MSK) have entered into a collaborative research agreement aimed at discovering new therapeutic targets for gastroesophageal malignancies.

  10. TuHURA Files Investigational New Drug Application For TBS-2025 In The Treatment Of Blood-Related Cancers 2/17/2026

    TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration's (FDA) Division of Hematologic Malignancies 1 (DHM1) for the study of TBS-2025, a novel VISTA inhibiting antibody, for the treatment of mutNPM1 relapsed/refractory (r/r) Acute Myeloid Leukemia (AML) in combination with a menin inhibitor.